Quanta Dialysis Technologies, a Warwick, UK-based company dedicated to transforming kidney care through its Quanta™ Dialysis System, raised over $60M in Series E funding.
The round was led by Novo Holdings, Glenview Capital and b2venture, with participation from existing investors.
The company intends to use the funds to expand its commercial presence in the US and continue to invest in innovation within the sector.
Led by CEO Alejandro Galindo, Quanta Dialysis Technologies is committed to making dialysis accessible to every patient, in every setting, with its Quanta Dialysis System, which provides the clinical versatility needed to deliver kidney replacement therapy across multiple care settings. The device is designed to be operated by a broad range of users to bring dialysis directly to patients.
In 2022, Quanta received clearance for the first and only FDA-cleared device able to perform intermittent hemodialysis (IHD), sustained low efficiency dialysis (SLED), and CRRT (CVVHD and SCUF) without any need for bags. In 2024, the company received FDA-clearance for home hemodialysis (HHD), offering a high dialysate flow (500 mL/min) system.
FinSMEs
18/11/2024